Clinical Trial Update: A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial of ustekinumab in Chinese participants with active systemic lupus erythematosus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lupus Erythematosus, Systemic | Phase 3 | Status: WITHDRAWN